Theradiag

Theradiag's mission is to advance personalized medicine through specialized diagnostic solutions for monitoring complex chronic diseases. The company has achieved a strong position in the European market for therapeutic drug monitoring of autoimmune diseases with its flagship Lisa-Tracker platform. Its strategy focuses on expanding its molecular diagnostics portfolio, forging strategic partnerships for commercial reach, and capitalizing on the growing demand for companion diagnostics in biotherapy management. As a publicly traded entity, Theradiag balances R&D investment with commercial execution to drive growth.

Theradiag's technology is built on dual pillars: immunoassay platforms (ELISA/FEIA) for therapeutic drug monitoring of biologics, and molecular diagnostics platforms (PCR/dPCR) for oncology biomarker detection and infectious disease monitoring.

Theradiag competes with large IVD conglomerates (e.g., Thermo Fisher, Roche) in molecular diagnostics and specialized immunoassay firms in TDM. Its differentiation lies in its deep focus on drug/antibody monitoring for biologics and its strategy of targeted partnerships and panel offerings in oncology.